Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LeY-CAR-T in advanced solid tumours
NCT03851146Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Nov 2016
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-LeY-CAR-transduced T cells in solid tumor, sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose-Limiting Toxicities at 4 weeks. Started Nov 2016; status: completed.
02
Drugs
Anti-LeY-CAR-transduced T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03851146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851146.